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Abstract
Background: Tobacco dependence is the leading cause of preventable death and disabilities worldwide and nicotine is the
main substance responsible for the addiction to tobacco. A vaccine against nicotine was tested in a 6-month randomized,
double blind phase II smoking cessation study in 341 smokers with a subsequent 6-month follow-up period.
Methodology/Principal Findings: 229 subjects were randomized to receive five intramuscular injections of the nicotine
vaccine and 112 to receive placebo at monthly intervals. All subjects received individual behavioral smoking cessation
counseling. The vaccine was safe, generally well tolerated and highly immunogenic, inducing a 100% antibody responder
rate after the first injection. Point prevalence of abstinence at month 2 showed a statistically significant difference between
subjects treated with Nicotine-Qb (47.2%) and placebo (35.1%) (P= 0.036), but continuous abstinence between months 2
and 6 was not significantly different. However, in subgroup analysis of the per-protocol population, the third of subjects
with highest antibody levels showed higher continuous abstinence from month 2 until month 6 (56.6%) than placebo
treated participants (31.3%) (OR 2.9; P= 0.004) while medium and low antibody levels did not increase abstinence rates.
After 12 month, the difference in continuous abstinence rate between subjects on placebo and those with high antibody
response was maintained (difference 20.2%, P= 0.012).
Conclusions: Whereas Nicotine-Qb did not significantly increase continuous abstinence rates in the intention-to-treat
population, subgroup analyses of the per-protocol population suggest that such a vaccination against nicotine can
significantly increase continuous abstinence rates in smokers when sufficiently high antibody levels are achieved.
Immunotherapy might open a new avenue to the treatment of nicotine addiction.
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Introduction
Despite the known health risks, people continue to smoke and
use tobacco primarily as a result of their addiction to nicotine [1].
Most smokers trying to quit on their own fail on the long term [2].
Different types of counseling and behavioral therapies can increase
abstinence rates [2]. Similarly, pharmacotherapies prescribed in
smoking cessation interventions, such as nicotine replacement
products, bupropion and the recently approved varenicline, help
smokers quit, but all current therapies have only modest efficacy
[2]. Consequently, there is a need for alternative and improved
treatments [3].
One novel approach is provided by immunization against
nicotine. The rationale is to induce antibodies which bind nicotine
in the blood, thereby preventing it from crossing the blood-brain
barrier [4,5]. Thus, the reinforcing action of nicotine in the brain,
which is the driving force in nicotine addiction and tobacco
smoking, should be reduced. Nicotine is a small non-immunogenic
molecule and must be conjugated to a carrier protein to induce
antibodies. Such nicotine conjugates have been shown to induce
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enough antibodies in animals to sequester the drug in the blood
[4,6] attenuate nicotine addiction [7] and prevent reinstatement of
nicotine seeking behavior in vaccinated animals [8].
A candidate vaccine against nicotine has been developed based
on a virus-like particle (VLP)-nicotine conjugate [9]. The
presentation of an antigen in a highly ordered, repetitive array,
such as protein shells or coats of certain viruses, provokes strong
antibody responses [10]. The coat protein of the bacteriophage
Qb forms non-infectious VLPs when expressed recombinantly in
Escherichia coli [11]. Using chemical cross-linkers, any antigen can
be placed directionally onto the VLP surface, rendering it highly
immunogenic. Antigens coupled to such VLPs induce potent and
long-lived antibody responses in mice [12] as well as humans
[9,13,14]. Specific antibodies of the IgG but not IgE isotype can be
detected, demonstrating that potent antibody responses may be
induced in the absence of isotypes causing allergic problems. For
the present vaccine, a nicotine derivative was chemically linked to
VLPs formed by the coat protein of the bacteriophage Qb. In pre-
clinical animal studies, this Nicotine-Qb vaccine induced strong
and specific IgG antibody responses [9].
In a phase I study 32 healthy non-smokers were immunized
with the Nicotine-Qb vaccine at doses of 50 mg and 100 mg in
presence or absence of Alum, one of the adjuvants approved for
use in humans [9]. A single injection induced an anti-nicotine
response in 100% of subjects, antibody levels were boosted by
either a second injection or by the addition of Alum, and the
vaccine was well tolerated. Based on these encouraging results, we
performed an exploratory phase II randomized trial in smokers
ready to quit.
We present the results of the 6-month randomized double blind
trial and the subsequent 6-month follow-up period of this trial
assessing immunogenicity, efficacy, safety and tolerability of the
vaccine against nicotine.
Methods
Design overview
The protocol synopsis for this trial and supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocol S1.
We performed a phase II randomized, double blind, placebo-
controlled trial. The study subjects were recruited through public
advertisements on billboards posted in the three clinical study
centers in Switzerland (Kantonsspital, St. Gallen, University
Hospital Center, Lausanne, and Hirslanden Lung Center, Zurich)
where the study was performed. Interested participants were asked
to call the study center. The trial was explained and a pre-
screening interview was undertaken. If the subjects met the initial
screening criteria, they were scheduled for a visit to provide
informed consent and to undergo a screening of their health and a
medical examination including standard clinical laboratory and
electrocardiogram. Participants did not receive any compensation.
We considered three main objectives. First, to assess the clinical
efficacy of Nicotine-Qb in smokers willing to quit, second, to
evaluate the safety and tolerability of Nicotine-Qb in smokers and
third, to determine the immunogenicity of Nicotine-Qb.
Participants
Participants were required to be between 18 and 70 years, to
have been smoking at least 10 but no more than 40 cigarettes/day
for more than 3 years, have a Fagerstro¨m Score of at least 5 at
screening [15], and willing to quit smoking. Women of
childbearing potential had to agree to use an effective form of
contraception during treatment and up to 12 months after the last
dose of the vaccine. Exclusion criteria were the following:
cardiovascular, renal, pulmonary, endocrine, or neurological
disorders, ulcers, skin disorders, autoimmune diseases or severe
allergies; risk behavior to acquire HIV; an active liver infectious
disease; a current diagnosis or a history of major depressive
episodes, of panic attacks, psychosis, bipolar or eating disorders;
use of other smoking-cessation treatments, like bupropion or
nicotine replacement therapy within 6 months before study
enrollment or at the time of screening; pregnancy or lactation;
abuse of alcohol or other recreational drugs; use of a psychoactive
drug (excluding sleeping pills) within one month before enroll-
ment; and regular use of any non-cigarette tobacco product.
We obtained written informed consent from all subjects before
they were enrolled in the study. The Ethics Committees of the
three centers (i.e., Lausanne Medical School Ethics Committee, St
Gallen: Ethics Committee of the Canton St. Gallen, Hirslanden:
Ethics Committee of the Canton Zurich) approved the study. The
Swiss health authorities were notified of its conduct and the study
protocol has been registered in the Swiss Medical Registry
(Swissmedic # 2003DR2327) and at www.clinicaltrials.org
(NCT 00369616).
Randomization and Interventions
Two thirds of the subjects were scheduled to receive five intra-
muscular injections of 100 mg Nicotine-Qb in Alum and one third
to receive indistinguishable placebo (Alum alone) at monthly
intervals, i.e., on months 0, 1, 2, 3, and 4. After having fulfilled the
eligibility criteria, investigators sent the subject’s identification
number to the local pharmacist, who assigned subjects to
treatment according to a randomization list, prepared using
standard software, with a block size of 15. All study personnel,
participants, study statisticians and data monitoring committee
were blinded to treatment assignment for the duration of the
study. A ‘‘target quitting date’’ was set at 1 month after the first
vaccination. Individual standardized counseling was provided
weekly to all study participants starting at week 3 after the first
vaccination until week 16 by health care professionals and
physicians trained through an effective smoking cessation program
[16]. The initial phase ended at month 6 and was followed by an
additional 6-month period of follow-up with two visits at months 9
and 12. Neither additional injections nor counseling was given
during the follow-up phase.
The active pharmaceutical agent was Nicotine-Qb, i.e., a
nicotine derivative coupled to the VLP Qb as a carrier. The VLP
is produced by recombinant expression of the coat protein of the
bacteriophage Qb in E. coli. The adjuvant used with Nicotine-Qb
was Alum (Alhydrogel: Brenntag Biosector A/S, Frederikssund,
Denmark), and the placebo consisted of Alhydrogel alone. All
materials for the clinical trial were produced to current good
manufacturing principles according to the International Confer-
ence on Harmonization guidelines. An injection volume of 2 ml
was given intramuscularly at the upper arm. The vaccine dose was
selected based on the results from the Phase I study which showed
an early onset, a maximal immune response with 100 mg Nicotine-
Qb and an about twofold increase of titers by the addition of
Alum. Additional information on the product, pre-clinical
toxicological safety studies, animal efficacy studies and the ELISA
are published elsewhere [9].
Outcomes and follow-up
The first primary outcome was abstinence from smoking
defined as self-reported abstinence from smoking, confirmed by
a carbon monoxide concentration in expired air of less than
10 ppm. Carbon monoxide was measured pre-study, at each
Nicotine Vaccine
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monthly visit after vaccination and during follow-up at months 9
and 12 with a Micro SmokerlyzerH (Bedfont). Study participants
were considered to be continuously abstinent when at all monthly visits
from month 3 until month 6 they declared themselves as being
non-smokers during that period and when the carbon monoxide
concentration in their exhaled air was below 10 ppm. We did not
use cotinine as a second confirmation means of abstinence because
the binding of nicotine to antibodies might prolong the elimination
of nicotine and its metabolite cotinine [17]. Point prevalence of
smoking or of abstinence was defined at each assessment visit as
the smoking status (self-report confirmed by CO below 10 ppm) of
a study participant at that visit, irrespective of his/her smoking
status on the visits before or after. Self-reported cigarette
consumption was recorded daily in paper and pencil diaries.
Subjects with missing visits or who were lost to follow-up at any
time during the study were considered as smokers. Given the
exploratory nature of this Phase II trial, the study protocol
stipulated that additional evaluations guided by the results might
be considered, in particular the correlation between the clinical
outcome and anti-nicotine antibody titers could be assessed.
The other primary outcomes were immunogenicity, safety and
tolerability of Nicotine-Qb. The immunogenicity was assessed by
determination of specific anti-nicotine antibodies of IgG isotype by
ELISA using an RNAse-nicotine conjugate [9] in sera before
vaccination and then at monthly intervals up to month 6 and at
months 9 and 12. Since a human anti-nicotine monoclonal IgG
reference standard was not available, nicotine-specific IgG levels
are reported as titers. The ELISA titer for each serum specimen
corresponds to the dilution needed to achieve an optical density of
50% of the optical density reached at saturation. An antibody
responder was defined as a subject who had an anti-nicotine IgG
titer, which was larger than the unspecific background reactivity
(average plus three standard deviations) of the ELISA. Background
reactivity of the ELISA was determined using preimmune sera.
Sub-group analyses were performed by using the area under the
curve (AUC) of log-transformed titers from month 3 to month 6.
Safety and tolerability were assessed through systematic
collection of vital signs and all reported symptoms, as well as
standard clinical laboratory and injection site examination in all
subjects. A specific safety check-up was performed one week after
each injection. Subjects also kept a diary for self-assessment of
local reactions. Information was collected about adverse events
that occurred during the double blind and follow-up periods. An
adverse event was any new undesirable medical occurrence, which
did not necessarily have to have a causal relationship with this
treatment. The classification of the severity was based on the
following scale. Mild: the adverse event was noticeable to the
individual; it did not require modification of the dose but may
have required additional therapy, such as paracetamol. Moderate:
the adverse event interfered with the individual’s daily activities; it
may have required additional therapy, but did not require
discontinuation of the study agent. Severe: the adverse event was
intolerable and necessitated additional therapy or discontinuing
the study agent. A serious adverse event was any untoward medical
occurrence that at any dose resulted in death, in persisting or
significant disability/incapacity, was life-threatening, required in-
patient hospitalization, or any significant medical event as judged
by the investigators.
To assess craving and withdrawals symptoms, we used two
questionnaires, the Questionnaire on Smoking Urges [18]
addressing two conditions (i.e., intention to smoke and anticipation
of relief from the urgent desire to smoke) and the Wisconsin
Withdrawal Scale [19] addressing craving, concentration, sleep-
lessness, anger, anxiety, sadness and hunger.
Statistical analyses
Statistical analyses were performed with SAS for Microsoft
WindowsH 9.1.3. Pearson Chi-Square test without correction was
used to calculate the statistical significance of the effect of
vaccination (active versus placebo) and the effect of antibody titer
levels (high, medium, low versus placebo) on continuous
abstinence and on point prevalence abstinence. For continuous
variables differences between two groups were analyzed with the
two-sample t-test or with the Mann-Whitney test as nonparametric
test, and, for more than two groups, with analysis of variance or
the Kruskal-Wallis test as nonparametric test. The influence of
baseline parameters on the abstinence rate was tested by means of
a logistic regression analysis (SAS ProcLogistic using the binary
logit model). Outcomes were considered significant if p values of
the respective statistical tests were smaller than 0.05. Nicotine
replacement users were excluded from the per-protocol analysis.
We powered our study on rates of continuous abstinence and
calculated a sample size that would detect a difference of at least
15% (smoking abstinence rates of at least 30% compared to 15%
on placebo) with an alpha error of 5% or less and a power of 90%
or more. We chose unbalanced group sizes with a ratio of 2:1 for
active vs. placebo treatment to allow as many study participants as
possible to potentially benefit from the active treatment and to
permit sub-group analyses of efficacy by antibody response. Based
on theses parameters, the required sample size was 300 subjects
(200 in the active group vs. 100 in the placebo group). Considering
the exploratory nature of this Phase II study, additional
participants were considered as valuable source of information.
Results
Participants
Enrollment of smokers started in December 2003 and was
completed in September 2004. Among the 377-screened smokers,
36 were excluded for various reasons as detailed (Figure 1).
Altogether 341 randomized subjects received at least one dose of
the study treatment (safety population). Their baseline character-
istics were similar across groups (Table 1). One additional subject
was excluded for the intention-to-treat analysis (Figure 1) because
of a violated key inclusion criterion, namely that he had already
stopped smoking at the baseline visit. Five immunizations with
Nicotine-Qb were administered at months 0, 1, 2, 3 and 4. The
target quit date was set to month 1 and smoking cessation
counseling started at week 3 and was performed until month 4.
Immunogenicity
Of the 340 subjects in the intention-to-treat population, 229
received the vaccine and 111 the placebo. For 5 subjects (2 vaccine/
3 placebo) only pre-immune sera were available for the immuno-
genicity analyses. No induction of nicotine-specific IgG antibodies
was observed for subjects receiving placebo. In subjects receiving
the active treatment, a 100% antibody responder rate was achieved
with a single injection of Nicotine-Qb. The second, third, fourth
and fifth immunization at months 1, 2, 3 and 4 boosted the nicotine-
specific IgG levels and peak titers were achieved at month 5, i.e. 4
weeks after the 5th injection (Figure 2). Thereafter, titers declined
up to month 12 with a half-life of about 90 days.
Smoking behavior in the intention-to-treat population
Continuous abstinence rates between month 3 and month 6 were
30.1% in the vaccine group and 26.1% in the placebo group, a non-
significant difference (P=0.44). Point prevalence abstinence rates at
month 2 were significantly different (P=0.036) between vaccine
group (47.2%) and placebo (35.1%). A higher point prevalence
Nicotine Vaccine
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abstinence rate of subjects vaccinated was maintained up to month
6, but the differences after month 2 were not significant.
We then investigated which variables influenced the continuous
abstinence rate in the intention-to-treat population by logistic
regression. No significant influence of treatment, age, gender,
bodyweight, number of cigarettes smoked, duration of smoking or
Fagerstro¨m score was detectable (all P.0.1). When the anti-
nicotine antibody titer at month 2 (available for 325 subjects,
corresponding to 95% of the intention-to-treat population) was
included in the analysis, a significant effect of the antibody titer on
the continuous abstinence rate was determined (P=0.027) while
the other variables showed no influence. The significant influence
of anti-nicotine levels on abstinence was also observed when only
the subjects in the vaccine group were analyzed (n=219,
P=0.018).
Antibodies induced by vaccination are expected to bind nicotine
in the blood, reduce its passage into the brain and thus interfere
with the reinforcing properties of nicotine e.g. during a lapse.
Thus, vaccination is not expected to reduce craving and
withdrawal during a smoking cessation attempt. Accordingly,
there was no detectable difference between vaccine and placebo
group on intention to smoke and on anticipation of relief from the
urgent desire to smoke as addressed by the Questionnaire Smoking
Urge, as well as on withdrawal symptoms using the Wisconsin
Withdrawal Scale (data not shown).
Safety and Tolerability
Table 2 shows an overview of adverse events in the 341
subjects of the safety population. Of the 9 serious adverse events
Figure 1. Flow Chart of Study Subjects.
doi:10.1371/journal.pone.0002547.g001
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reported in 8 participants, only one might be related to the study
treatment. This occurred in a 60-year old woman who reported
flu-like symptoms associated with chest pain. However, there was
no evidence for heart disease and at the 6-month follow-up the
participant was free of any cardiovascular or pulmonary diseases.
The majority of all adverse events were mild to moderate (95.7%)
and only 4.3% of events were rated as severe. These were mainly
concurrent infections equally distributed between active treatment
and placebo groups, and systemic or local reactions, which were
more prevalent on active treatment. The most prominent systemic
adverse event was reported as ‘‘flu-like symptoms’’ by 69.4% of
vaccinated subjects compared to 12.5% of placebo subjects
(Table 3). These symptoms usually appeared 2–12 hours after
injection and disappeared 24 hours post dose. There were several
other adverse events which seem to be related to the flu-like
syndrome but were reported separately such as pyrexia, headache,
chills and myalgia with a significantly higher incidence on
treatment group as specified by the OR and its 95% CI
(Table 3). Severe pyrexia was observed in 3 out of 194 reports
(1.5%) and flu-like symptoms were rated as severe in 7 out of 344
reports (2.0%). Paracetamol was prescribed for amelioration of
symptoms if necessary. If analyzed over time, the incidence
(percent of subjects affected per injection period) of flu-like
symptoms showed an increase from 21% (1st injection period) to
44% (2nd) and thereafter declined to 40% (3rd), 25% (4th) and 24%
(5th injection period). Among the local reactions, pain at the
injection site was the most prevalent symptom, whereas local
swelling, erythema and edema were rarely reported. There was no
difference in the incidence of flu-like symptoms between the 3
subgroups (based on anti-nicotine antibody levels as defined below)
and no significant difference in efficacy between subjects who had
flu-like symptoms and those without (P=0.21).
Table 1. Baseline characteristics of subjects.
Safety Population Per Protocol Population*
N=341 N=239
Nicotine-Qb Placebo Nicotine-Qb Nicotine-Qb Nicotine-Qb Placebo
High Medium Low
Ab responders Ab responders Ab responders
N=229 N=112 N=53 N=53 N=53 N=80
Male gender, % 59 58 68 55 62 61
Age**, years 42.1 (36.6 ; 48.5) 42.1 (36.3 ; 47.9) 43.2 (36.0 ; 48.9) 41.5 (38.8 ; 46.3) 41.3 (35.6 ; 48.0) 41.5 (34.4 ; 48.2)
Number of cig. smoked/day** 25 (21 ; 32) 25 (20 ; 35) 25 (20 ; 35) 25 (22 ; 33) 25 (21 ; 30) 27 (22 ; 35)
Number of years smoked** 25 (19 ; 31) 25 (19 ; 31) 27 (19 ; 31) 24 (19 ; 31) 25 (18 ; 30) 25 (19 ; 32)
CO ppm exhaled air** 29 (20 ; 38) 27 (21 ; 40) 25 (16 ; 31) 28 (23 ; 37) 30 (20 ; 37) 28 (21 ; 40)
Fagerstro¨m score, range (1–10)** 7 (6 ; 8) 7 (6 ; 7) 7 (6 ; 8) 7 (6 ; 8) 7 (6 ; 7) 6 (6 ; 7)
Number of previous quitting attempts** 3 (2 ; 4) 3 (2 ; 4) 3 (2 ; 4) 3 (1 ; 5) 3 (2 ; 4) 3 (2 ; 4)
Ab Antibody titer.
*Nicotine replacement therapy users and subjects with missing titers at months 4 to 6 were excluded; the participants on active treatment were separated into three
responder subgroups according to their antibody titers: high, medium, and low antibody titer levels.
**Median values (25% ; 75% quartiles).
doi:10.1371/journal.pone.0002547.t001
Figure 2. Geometric mean nicotine-specific IgG titers (695%
CI) (Active, N=227; placebo, N=108).
doi:10.1371/journal.pone.0002547.g002
Table 2. Overview of Adverse Events in the safety
population.
Vaccine Placebo
N=229 N=112 Odds ratio
# n % # n % OR (95% CI)
Total AEs 1683 225 98.3 426 104 92.9 4.3 (1.3–14.7)
Mild 1149 221 96.5 279 95 84.8 4.9 (2.1–11.8)
Moderate 468 167 72.9 122 66 58.9 1.9 (1.2–3.0)
Severe 66 48 21.0 24 15 13.4 1.7 (0.9–3.2)
Serious AEs 6 * 5 2.2 3 ** 3 2.7 0.8 (0.2–3.5)
Related AEs 864 199 86.9 73 41 36.6 11.5 (6.7–19.8)
# Total number of adverse events.
n Number of subjects who experienced at least one event of the respective
category. A subject, who had e.g. one mild and one moderate event was
counted in both categories.
(%) Percentages of subjects with at least one event, calculated on the total
number of subjects in the respective groups.
OR odds ratio; CI confidence interval; AEs adverse events.
*Limb operation, Pneumonia, Head trauma, Disc prolapsed, Crime victim, Chest
pain.
**Minor surgery, Osteomyelitis, depression.
doi:10.1371/journal.pone.0002547.t002
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Smoking behaviour in the per protocol analysis
Given the significant effect of the antibody titer on the
continuous abstinence rate, we then analyzed the per-protocol
population according to antibody levels to explore the relationship
between titers and efficacy. Given the highest differences in point
prevalence abstinence rate between vaccine and placebo groups at
month 2, we explored continuous abstinence from month 2
onwards, and used continuous abstinence from month 2 until
month 6 for all exploratory evaluations. We excluded the subjects
who concomitantly used nicotine replacement therapy (n=44)
(Figure 1). Nicotine replacement therapy (NRT) is a self-
medication available over-the-counter in Switzerland. The study
protocol stated that nicotine replacement therapy use should be
discouraged since it is believed to have a different effect on the two
treatment groups. NRT products, e.g. nicotine patches, release
nicotine into the blood. The nicotine from NRT might saturate
the nicotine-specific antibodies induced by vaccination. Accord-
ingly, the antibodies would not be available any more for binding
nicotine from a lapse and thus, the effect of the nicotine vaccine
would be diminished or even abolished. Vice versa, when nicotine
from the NRT is bound to antibodies, its passage to the brain is
reduced and the effect of the NRT would also be diminished. In
contrast, in smokers on placebo nicotine replacement therapy may
exert its documented positive effect. Therefore, subjects concom-
itantly using NRT were excluded. After exclusion, none of the
baseline characteristics were different between the groups treated
with the vaccine (n=199) or placebo (n=97).
For the correlation with antibody titers, all subjects who had
performed the scheduled visits and blood samplings were included.
The individual AUC of anti-nicotine IgG titers could not be
calculated for subjects with incomplete titer values because of
missing one or several visits (n=57). The 2:1 randomization ratio
was preserved in this per protocol population (vaccine n=159,
placebo n=80) and baseline characteristics of excluded and
included subjects were not significantly different. The 159
Nicotine-Qb treated subjects were divided into three equal-sized
categories based on AUC tertiles. Low, medium, and high
responder groups were thus defined, each containing 53 subjects.
We divided subjects into three equal groups to have the minimal
number of points required to study the relationship between
antibody titers and efficacy outcomes. The baseline characteristics
of these subgroups were similar (Table 1) and the three groups
showed a similar time course of the immune response with peak
titers seen at month 5. They differed only in the magnitude of
nicotine-specific IgG titers achieved (Figure 3).
Overall, there was a statistically significant difference in
continuous abstinence rates from month 2 until month 6 among
Table 3. Adverse Events with an incidence across all 5
injections of at least 10% of subjects in either group.
Nicotine-Qb Placebo
N=229 N=112 Odds ratio
# n % # n % OR (95% CI)
Flu-like symptoms 325 159 69.4 19 14 12.5 15.9 (8.5–29.8)
Pyrexia 184 96 41.9 10 9 8.0 8.3 (4.0–17.1)
Headache 171 92 40.2 55 30 26.8 1.8 (1.1–3.0)
Nasopharyngitis 89 73 31.9 34 29 25.9 1.3 (0.8–2.2)
Injection site pain 68 45 19.7 3 2 1.8 13.5 (3.2–56.5)
Rigors (Chills) 47 31 13.5 0 0 0.0 —
Myalgia 46 31 13.5 6 6 5.4 2.8 (1.1–6.8)
Back pain 31 25 10.9 13 12 10.7 1.0 (0.5–2.1)
Weight increased 24 24 10.5 13 13 11.6 0.9 (0.4–1.8)
Rhinitis 26 21 9.2 19 12 10.7 0.8 (0.4–1.8)
Influenza 18 16 7.0 14 12 10.7 0.6 (0.3–1.4)
# Number of events.
n number of subjects with at least one event.
% Percentages of subjects with at least one event, calculated on the number of
subjects in the respective groups.
OR odds ratio.
CI confidence interval.
doi:10.1371/journal.pone.0002547.t003
Figure 3. Nicotine-specific geometric mean IgG titers (695 confidence interval) in the per protocol population (N=229).
doi:10.1371/journal.pone.0002547.g003
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the 3 subgroups (low, medium and high titer groups) and placebo
(P=0.012, Table 4). While there was no difference between
abstinence rates of subjects on placebo and the subjects with either
low or medium antibody response, the difference between subjects
on placebo (31.3%) and the subjects with a high antibody response
(56.6%) was both clinically relevant (25.3% more abstainers in the
high antibody response group) and statistically significant
(P=0.004). The odds ratio for continuous abstinence with high
antibody titers vs. placebo was 2.9 (95% CI 1.4–5.9). Inclusion of
nicotine replacement therapy users in the analysis did not change
the overall outcome: there was a statistically significant overall
difference (P=0.025) of abstinence rates across the 3 subgroups
(low-medium-high titers) and placebo. The difference between
placebo (28.6%) and the participants with a high antibody
response (50%) was again both clinically relevant (difference
21.4%) and statistically significant (OR 2.5 (95% CI 1.3–4.9);
P=0.008).
At 12-month follow-up, increased abstinence in the high
responder group was maintained. The difference between
participants on placebo (21.3%) and those with high antibody
response (41.5%) was both clinically relevant (difference 20.2%)
and statistically significant (OR 2.6 (95% CI 1.2–5.7); P=0.012).
Regarding point prevalence rates, the maximum effect was
reached already at month 2, i.e. 4 weeks after the second dose of
the vaccine (Figure 4). The subgroup of 53 subjects with high
antibody titers showed a clear separation from placebo from
month 2 onwards. At month 2, point prevalence abstinence rate
was 77.4% for subjects with high antibody response and 46.8% for
placebo (OR 3.9 (95% CI 1.8–8.5); P=0.0005) (Figure 4). The
difference in abstinence rates between high antibody responders
and placebo was statistically significant at all time points between
months 2 and 6 (all P,0.012). The abstinence rate of the group
with medium titers separated from placebo at month 2, without
reaching statistical significance (absolute difference 13.6%,
P=0.13), and then reverted towards placebo rates at month 6.
There was no indication that some subjects might have
increased their smoking with the vaccine (i.e., no compensatory
smoking) (Figure 5). In contrast subjects who had high antibody
titers, but were non-abstainers as assessed by continuous
abstinence, even showed a tendency for lower cigarette consump-
tion. Data on carbon monoxide in exhaled air were in agreement
with the reduction in number of cigarettes smoked (Table 5).
Discussion
All subjects who received Nicotine-Qb produced a nicotine-
specific IgG antibody response after the first dose of Nicotine-Qb.
This response increased with further injections. No demographic,
clinical or smoking-related baseline variable was found to have an
effect on antibody titers.
Despite the 100% antibody responder rate, in the intention-to-
treat population, vaccination against nicotine did not significantly
increase continuous abstinence rates. This could have been caused
by two reasons: First, sequestration of nicotine by antibodies in
blood might not be sufficient for increasing abstinence rates in
smokers. Second, vaccination against nicotine–similar to prophy-
lactic vaccinations against infectious diseases-induces a certain
distribution of antibody levels in the different subjects. Thus, the
second reason for failure could have been that average antibodies
levels induced in this study were not high enough to show a
significant effect in the ITT population. The study presented here
was the first clinical study testing a nicotine vaccine in a smoking
cessation setting. It was therefore unknown which antibody levels
had to be achieved. Two findings indicate the second reason is more
likely to be correct. Logistic regression showed that antibody titer is
the only variable which had a significant effect on continuous
abstinence and, more importantly, subgroup analyses based on the
antibody titers revealed a statistically significant and clinically
relevant increase in continuous abstinence from month 2 until
month 6 among subjects with high titers compared to placebo, but
not in subjects with medium and low titers. At month 12, the
significant difference in continuous abstinence between participants
on placebo and those with high antibody response was maintained.
The finding that significant efficacy is only seen for the high
responder group fits with the mechanistic explanation that a
sufficient amount of anti-nicotine antibodies is required to
sequester the nicotine in the event of a slip. Although based on
a subgroup analysis, this suggests a proof of the concept that
vaccination against nicotine can increase abstinence rates. High
antibody titers were the only factor related to sustained smoking
cessation. The separation of abstinence rates already at month 2
between subjects with high titers and those with either low titers or
on placebo suggests that not only high titers, but also an early rise
of titers seems to be crucial for success. The hypothesis generated
from this trial will have to be confirmed in an ITT population in a
prospective confirmatory trial.
Table 4. Continuous abstinence rates from months 2 to 6 in
the per protocol population*.
Total Abstainers
N N % 95% CI P value**
Vaccinated subjects 159 64 40.3 32.6–47.9 0.174
High Ab responders 53 30 56.6 43.3–70.0 0.004
Medium Ab responders 53 17 32.1 19.5–44.6 0.920
Low Ab responders 53 17 32.1 19.5–44.6 0.920
Placebo 80 25 31.3 21.1–41.4
CI Confidence interval.
Ab Antibody titers.
*nicotine replacement therapy users and subjects with missing titers were
excluded; the participants on active treatment were separated into three
responder groups according to their antibody (Ab) titers: high, medium, and
low antibody titer levels.
**vs. placebo.
doi:10.1371/journal.pone.0002547.t004
Figure 4. Point prevalence of smoking abstinence per antibody
responder group.
doi:10.1371/journal.pone.0002547.g004
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The vaccine was safe and generally well tolerated. The most
prevalent local adverse event was pain at the injection site and the
most frequent systemic adverse event was transient flu-like
symptoms. While side effects were common, they were self-
limited. The clinical trials assessing a VLP-based HPV vaccine
also reported mild injection sites reactions [20]. The fact that flu-
like symptoms were present in 69% of the subjects on active
treatment, as compared to 12.5% of those on placebo, might
Figure 5. Mean daily number of cigarettes smoked by non-abstainers per antibody responder group at the respective visit.
doi:10.1371/journal.pone.0002547.g005
Table 5. Carbon Monoxide Concentration* in Exhaled Air, per protocol population, in all subjects and per antibody responder
group.
Month
0 1 2 3 4 5 6 9** 12**
All subjects (N = 159), mean 28.0 5.0 3.0 3.0 3.0 4.0 6.0 12.0 12.0
Percentiles 25; 75 19; 36 2; 19 2; 15 2; 20 1; 20 1; 25 1; 23 1; 26 1; 28
n = 153 n= 146
High (N = 53), mean 25.0 3.0 2.0 2.0 2.0 2.0 2.0 3.0 3.5
Percentiles 25; 75 16; 31 1; 14 2; 5 2; 3 1; 5 1; 6.5 1; 7 0; 17 0; 22
n = 51 n= 50
Medium (N= 53), mean 28.0 6.0 3.0 6.0 5.0 14.0 14.0 16.0 18.5
Percentiles 25; 75 23; 37 2; 24 2; 13 2; 21 1; 21 1; 23 2; 26 2; 30 2; 27
n = 52 n= 50
Low, (N = 53), mean 30.0 6.0 9.0 13.0 10.0 17.5 12.0 15.5 12.5
Percentiles 25; 75 20; 37 2; 23 2; 19 2; 26 2; 25 2; 29 2; 26 2; 28 2; 30
n = 50 n= 46
Placebo, (N = 80) 28.0 7.0 5.0 8.5 12.0 14.0 14.0 18.0 19.0
Percentiles 25; 75 21; 40 2; 22 2; 19.5 2; 27.5 2; 23.5 2; 31.5 2; 30 2; 30 2; 31
n = 77 n= 75
*Mean and percentiles 25%–75%.
**Not all subjects returned for 9- and 12-months follow-up visits.
Carbon monoxide concentration expressed in ppm.
High = Subgroup of subjects with high anti-nicotine antibody levels.
Medium= Subgroup of subjects with medium anti-nicotine antibody levels.
Low= Subgroup of subjects with low anti-nicotine antibody levels.
doi:10.1371/journal.pone.0002547.t005
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suggest that the study was essentially unblinded for many subjects.
However, there was no difference in the incidence of flu-like
symptoms in the 3 groups with low, medium and high antibody
titers. The fact that significant abstinence was only achieved in the
group with high antibody titers, while medium and low responders
had similar abstinence rates as placebo, clearly demonstrates that
flu-like symptoms did not influence abstinence rates. Self-reported
cigarette consumption and carbon monoxide measurement
showed that vaccinated smokers who did not achieve abstinence
did not increase smoking to compensate for the potentially lower
nicotine amounts reaching the brain in the presence of anti-
nicotine antibodies.
Our study results have several limitations. First, whereas the
percentage of smoking abstinence (as defined by self-reported
smoking status and CO levels smaller than 10 ppm at the monthly
visits) in the active group (30.1%) was similar to the one
anticipated and used for the sample calculation (30%), the
percentage of smoking abstinence in the placebo group (26.1%)
was unexpectedly high. The abstinence rate for placebo is similar
to that usually found in phase III trials for active treatment using
NRT and even higher than the one showed for the bupropion
group (20.2%) of the trial comparing efficacy between varenicline,
bupropion and placebo [21]. This might be due to differences in
the population. Smokers who volunteered for our study had placed
very high expectations in the study per se, as illustrated by the very
high baseline mean of motivation to stop smoking (8.5 on a visual
analog scale from 0 to 10 for subjects in both groups) and
confidence in succeeding (7.8 on a visual analog scale from 0 to 10
in subjects randomized to vaccine and 7.7 in those to placebo). In
addition, the study participants might have been positively
influenced by the quality of the smoking cessation counseling
provided by the trained and motivated health care professionals
involved in subject recruitment and those involved in the study
accomplishment and follow-up [16]. Second, 57 subjects were
excluded for the per-protocol analysis based on AUC. However,
these excluded subjects represented a minority (19%) and the
baseline characteristics of included and excluded subjects were
similar, suggesting a low risk of selection bias. Third, we excluded
nicotine replacement therapy users because vaccine and nicotine
replacement therapy products could be expected to neutralize
each other, whereas in smokers on placebo nicotine replacement
therapy should exert its positive effect. The main finding of the
study was nevertheless not affected when the nicotine replacement
therapy users were included, namely that the individuals
generating a high antibody response achieved a higher abstinence
rate compared to the placebo group.
Immunotherapy has the potential to open a new avenue to the
treatment of nicotine addiction [22,23]. Safety and immunoge-
nicity of a second vaccine, NicVax, has recently been reported in a
small non-cessation study involving 14–23 subjects per group [23].
Despite the non-cessation design of the study, if a participant
expressed the desire to quit, a brief counseling and a treatment
manual was provided. A significantly higher 30-day abstinence,
which might have been at any time during the 9-month study, was
reported for the highest dose group compared to the placebo
group. However, it was not reported whether the proportion of
subjects who expressed the desire to quit and made a quit attempt
was similar between groups [23].
The antibodies induced by Nicotine-Qb have high specificity
for nicotine and do not cross-react with acetylcholine, the
endogenous ligand for nicotinic receptors [9]. In the intention-
to-treat analysis the differences in continuous abstinence were non-
significant, likely because at the given dose only one third of the
subjects achieved sufficient antibody levels. Sufficient binding of
nicotine by antibodies is required to reduce the amount of nicotine
entering the brain to sub-pharmacological levels. This appears to
be critical to block the reinforcing effect of nicotine and thereby to
the success of the vaccine. Meanwhile it has been possible to
significantly increase anti-nicotine antibody levels and decrease the
incidence of flu-like symptoms by reformulating the vaccine (P.
Mu¨ller, unpublished results). Although a nicotine vaccine is not
expected to address all aspects of tobacco dependence [24], our
results indicate that antibodies sequestering nicotine in serum
might help smokers quit.
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